Cook Medical, Inc., IVC Filters

With 6,501 pending actions more than a decade after centralization, the Cook Medical IVC filter docket remains one of the larger active mass-tort dockets by volume, built on claims that inferior vena cava filters — implanted to prevent blood clots from reaching the lungs — can fracture, migrate, tilt, or perforate the vena cava wall, in some cases requiring complex retrieval procedures. A pending-action count this large, sustained this long after centralization, points to a docket where bellwether trials and years of device-design and warnings discovery have already built a substantial factual record, but where a comprehensive global settlement has not yet resolved the bulk of the inventory.

For a funder or portfolio-finance allocator, that combination — large volume, mature factual record, no comprehensive settlement closing out the docket — is a distinct profile from either an early-stage filing wave or a post-settlement residual tail. Claims can be evaluated with real evidentiary grounding (established device-failure mechanisms, retrieval-complication data, and prior bellwether outcomes as comparables), while duration risk remains meaningfully open since the timing and structure of any eventual global resolution is not yet fixed by a completed settlement.

Inventory finance against a meaningful book of these claims is a reasonable structure for a firm with real volume, with underwriting weighted toward each claimant's filter-complication severity — fracture, migration, perforation, and retrieval difficulty vary widely in both medical severity and litigation strength. Medical-lien considerations are substantial here given that filter retrieval, especially for embedded or fractured filters, can require advanced interventional or surgical procedures with significant associated cost.

Because this docket has not resolved through a single comprehensive settlement, duration risk should be underwritten with meaningful variance built in rather than assuming a near-term liquidity event. Criterica Capital's mass-tort finance and medical-lien receivables products both apply, sized to reflect that open-ended duration profile.

Criterica Intelligence's structural brief on this docket covers the bellwether history and device-failure categories driving remaining claim variation in more depth.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.